“Recombinant Influenza Vaccination in U.S. Nursing Homes”
Based on recent evidence on the mutation of the A/H3N2 strain in egg-grown vaccine, the investigators will study the quadrivalent recombinant influenza vaccine (RIV4, Flublok) compared to the standard dose quadrivalent vaccine (IV4) in a cohort of long-stay NH residents with a primary endpoint of all-cause respiratory-related hospitalization.
Biological - Recombinant Influenza Vaccine
Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.
Biological - Standard Dose Quadrivalent Influenza Vaccine
Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
Comparative Effectiveness of Recombinant Versus Standard Dose Quadrivalent Influenza Vaccine in U.S. Nursing Homes
NCT03965195
dJ6xKd